Recursion Pharmaceuticals (RXRX) Current Leases (2020 - 2026)

Recursion Pharmaceuticals has reported Current Leases for 7 years, with the latest figure at $13.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 10.41% year-over-year to $13.1 million; the trailing twelve-month figure through Mar 2026 stood at $13.1 million (up 10.41% YoY), and the FY2025 full-year result was $12.7 million, down 8.21% from the prior year.
• Current Leases for Q1 2026 stood at $13.1 million, up from $12.7 million in the prior quarter.
• The five-year high for Current Leases was $13.8 million in Q4 2024, with the low at $4.1 million in Q1 2022.
• Historically, Current Leases has averaged $8.2 million across 5 years, with a median of $6.1 million in 2023.
• Annual changes were most pronounced in 2022 — Current Leases jumped 950.5% — and 2025, when it slipped 8.21%.
• Recursion Pharmaceuticals' Current Leases stood at $6.0 million in 2022, then climbed by 2.76% to $6.1 million in 2023, then surged by 125.56% to $13.8 million in 2024, then retreated by 8.21% to $12.7 million in 2025, then climbed by 3.35% to $13.1 million in 2026.
• The last three Current Leases figures came in at $13.1 million (Q1 2026), $12.7 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.